報價延遲最少15分鐘:2025/03/28 06:53 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
157.94 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-6.53/2.07
|
|
企業價值
9.88B
|
| 資產負債 |
|
每股賬面淨值
-1.91
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
363.64M
|
|
每股收益
2.68
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/03/28 06:53 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America. |